BRPI0716320A2 - Método para reduzir a absorção de fosfato em um individuo animal humano e não- humano e método para reduzir a absorção de fosfato em um individuo humano - Google Patents

Método para reduzir a absorção de fosfato em um individuo animal humano e não- humano e método para reduzir a absorção de fosfato em um individuo humano

Info

Publication number
BRPI0716320A2
BRPI0716320A2 BRPI0716320-7A2A BRPI0716320A BRPI0716320A2 BR PI0716320 A2 BRPI0716320 A2 BR PI0716320A2 BR PI0716320 A BRPI0716320 A BR PI0716320A BR PI0716320 A2 BRPI0716320 A2 BR PI0716320A2
Authority
BR
Brazil
Prior art keywords
human
individual
phosphate absorption
reducing phosphate
reducing
Prior art date
Application number
BRPI0716320-7A2A
Other languages
English (en)
Inventor
Mark Cook
Martin Petrovich
Erica Hellestad
Original Assignee
Wisconsin Alumni Res Found
Aovatechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Res Found, Aovatechnologies Inc filed Critical Wisconsin Alumni Res Found
Publication of BRPI0716320A2 publication Critical patent/BRPI0716320A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
BRPI0716320-7A2A 2006-10-26 2007-10-23 Método para reduzir a absorção de fosfato em um individuo animal humano e não- humano e método para reduzir a absorção de fosfato em um individuo humano BRPI0716320A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85455006P 2006-10-26 2006-10-26
PCT/US2007/082236 WO2008067084A2 (en) 2006-10-26 2007-10-23 Methods for reducing phosphate absorption

Publications (1)

Publication Number Publication Date
BRPI0716320A2 true BRPI0716320A2 (pt) 2014-02-25

Family

ID=38983491

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0716320-7A2A BRPI0716320A2 (pt) 2006-10-26 2007-10-23 Método para reduzir a absorção de fosfato em um individuo animal humano e não- humano e método para reduzir a absorção de fosfato em um individuo humano
BRPI0716317A BRPI0716317A8 (pt) 2006-10-26 2007-10-23 método para reduzir a absorção de fosfato em um indivíduo animal humano ou não-humano e método para reduzir a absorção de fosfato em um indivíduo humano

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0716317A BRPI0716317A8 (pt) 2006-10-26 2007-10-23 método para reduzir a absorção de fosfato em um indivíduo animal humano ou não-humano e método para reduzir a absorção de fosfato em um indivíduo humano

Country Status (8)

Country Link
US (2) US8877198B2 (pt)
EP (2) EP2081963A2 (pt)
JP (3) JP5701504B2 (pt)
CN (2) CN101583627A (pt)
AU (2) AU2007309026B2 (pt)
BR (2) BRPI0716320A2 (pt)
CA (2) CA2667563A1 (pt)
WO (2) WO2008051977A2 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008051980A2 (en) 2006-10-25 2008-05-02 Wisconsin Alumni Research Foundation Methods of reducing phosphate absorption
CN101583627A (zh) 2006-10-26 2009-11-18 威斯康星大学校友研究基金会 减少磷酸盐吸收的方法
CA2739545C (en) * 2008-10-17 2018-09-25 Fresenius Medical Care Holdings, Inc. Method of determining a phosphorus binder dosage for a dialysis patient
EP3556398A1 (en) * 2018-04-16 2019-10-23 Croda Denmark A/S Phytates for use as a biomolecules delivery or adsorption system

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0225254B1 (en) * 1985-11-25 1994-03-16 Ghen Corporation Specific antibody-containing substance from eggs and method of production and use thereof
US5496545A (en) 1993-08-11 1996-03-05 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
AU1526995A (en) * 1994-01-13 1995-08-01 Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations, The Antibodies specific for d-myo-inositol 1,4,5-trisphosphate
ATE238810T1 (de) * 1994-08-05 2003-05-15 Wisconsin Alumni Res Found Cck-antikörper zur verbesserung der futterverwertung
ES2162658T3 (es) 1996-03-05 2002-01-01 Mitsubishi Chem Corp Utilizacion de resinas intercambiadoras anionicas para la fabricacion de un medicamento destinado al tratamiento de la hiperfosfatemia.
US6180094B1 (en) 1996-07-19 2001-01-30 Nikken Chemicals Co., Ltd. Remedies for hyperphosphatemia
US6423754B1 (en) * 1997-06-18 2002-07-23 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with polyallylamine polymers
US5985938A (en) * 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
CH694588A5 (de) * 1999-02-09 2005-04-15 Hoffmann La Roche Menschliche intestinale Npt2B.
US6213930B1 (en) * 1999-03-15 2001-04-10 Wisconsin Alumni Research Foundation Method of using anti-phospholipase A2 antibodies to enhance growth or improve feed efficiency
US6346247B1 (en) * 1999-10-28 2002-02-12 Promega Corporation Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies
US7355092B2 (en) * 1999-12-27 2008-04-08 Ronald Marquardt Genetic vaccines for the production of chicken egg-yolk antibodies against enterotoxigenic Escherichia coli and other pathogens
AU2001271880A1 (en) * 2000-07-06 2002-01-21 Deltagen, Inc. Transgenic mice containing targeted phosphatase gene disruptions
ES2393674T3 (es) * 2003-11-14 2012-12-27 Brigham And Women's Hospital, Inc. Métodos para modular la inmunidad
JP4886983B2 (ja) * 2004-12-09 2012-02-29 アサマ化成株式会社 抗体を含有する機能性組成物
WO2008051980A2 (en) 2006-10-25 2008-05-02 Wisconsin Alumni Research Foundation Methods of reducing phosphate absorption
CN101583627A (zh) * 2006-10-26 2009-11-18 威斯康星大学校友研究基金会 减少磷酸盐吸收的方法

Also Published As

Publication number Publication date
US20100233184A1 (en) 2010-09-16
WO2008067084A2 (en) 2008-06-05
CA2667563A1 (en) 2008-05-02
AU2007325459A1 (en) 2008-06-05
US20100143385A1 (en) 2010-06-10
BRPI0716317A8 (pt) 2019-02-05
CA2667613A1 (en) 2008-06-05
WO2008067084A3 (en) 2008-07-31
AU2007309026A1 (en) 2008-05-02
JP5701504B2 (ja) 2015-04-15
CN101583627A (zh) 2009-11-18
EP2081963A2 (en) 2009-07-29
AU2007309026B2 (en) 2013-09-12
WO2008051977A8 (en) 2009-05-28
WO2008051977A3 (en) 2008-07-03
BRPI0716317A2 (pt) 2014-02-25
JP2014237591A (ja) 2014-12-18
EP2076543A2 (en) 2009-07-08
US8877198B2 (en) 2014-11-04
WO2008051977A2 (en) 2008-05-02
CN101595131A (zh) 2009-12-02
JP2010508281A (ja) 2010-03-18
EP2076543B1 (en) 2016-01-27
JP2010508282A (ja) 2010-03-18

Similar Documents

Publication Publication Date Title
BRPI0819075A2 (pt) Método para tratar púrpura em um indivíduo e método para diminuir a púrpura em um indivíduo antes de um procedimento cirúrgico
BRPI0914090A2 (pt) sistema de redução e método para reduzir um período de penalidade para um trem de potência distribuida
EP1800120A4 (en) METHODS AND SYSTEMS FOR PROVIDING AN INDIVIDUAL ANIMAL-SPECIFIC ALICAMENT PROGRAM
EP2207595A4 (en) SYSTEM AND METHOD FOR THE TREATMENT OF ANIMAL TISSUE USING LASER LIGHT
EP2085882A4 (en) MULTI-PROCESSOR SYSTEM, SYSTEM CONFIGURATION METHOD IN MULTI-PROCESSOR SYSTEM, AND PROGRAM THEREOF
BRPI0722059A2 (pt) Método para incorporar matriz de silício existente dentro de pilha integrada de 3d
BRPI0908656A2 (pt) ''método para reduzir a corrosão de sensor em artigos absorventes''
BRPI0906683A2 (pt) método para medir e caracterizar microvesículas em fluidos corporais humanos
BRPI0812292A2 (pt) Aparelho e método para gerenciar fornecimento de aditivo em locais de poço
GB0801176D0 (en) Device and method for use in construction
DE502007005036D1 (de) Vorrichtung zur energieabsorption
BRPI0613893A2 (pt) sistema e método para tratar pele
DE602007011544D1 (de) Batterieverwaltungssystem und Antriebsverfahren
CL2007002965A1 (es) Metodo y sistema para entregar y ejecutar las mejores practicas en proyectos de desarrollo de yacimiento petrolifero.
EP2126702A4 (en) ANALYSIS AND SYSTEM MANAGEMENT
GB2451561B (en) System and method for providing power in a well
IL179453A0 (en) Laser based counter measures system and method
BRPI0822095A2 (pt) Método para reduzir o sangramento e/ou hematoma em um paciente
BRPI0720604A8 (pt) composição e método para detecção de desmineralização
BRPI0915698A2 (pt) método para medir o conteúdo de água em um composto e dispositivo de medição de conteúdo de água
BRPI0819642A2 (pt) Método para a formação de uma dentadura para um paciente em uma única visita, e, dentadura
TWI350182B (en) Pharmaceutical compositions and method for treating inflammation in cattle and other animals
BRPI0913342A2 (pt) métodos e aparelho para redução de potência em um transceptor
EP2213243A4 (en) METHOD FOR EVALUATING EFFICACY; DEVICE FOR ASSESSING EFFICACY AND PROGRAM FOR EVALUATING THE EFFECTIVENESS OF A TOPICAL SKIN PREPARATION
BRPI0815176A2 (pt) Método e sensor para perceber moedas para avaliação

Legal Events

Date Code Title Description
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 6A E 7A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2277 DE 26/08/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A, 8A, 9A, 10A, 11A, 12A E 13A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.